SandboxAQ will partner with Sanofi, a global pharmaceutical and healthcare company, to locate biomarkers during clinical development.
Using SandboxAQ’s quantitative AI models, the project aims to filter knowledge graphs to gain a better understanding of human biology, supporting scientists’ ability to promote trust throughout investigational medicines and clinical development, the AI and quantum technology company announced Tuesday.
Nadia Harhen, general manager of AI simulation at SandboxAQ, said, “The application with Sanofi focused on biomarker identification is very exciting as it increases our reach into later-stage clinical development and the patient benefit that can be unlocked far beyond the early stages of drug discovery.”
SandboxAQ’s Large Quantitative AI Models
SandboxAQ’s large quantitative models — or LQMs — are trained on numerous data streams including proprietary data produced by the company’s algorithms. SandboxAQ’s LQMs avoid the barriers in scale and accuracy critical to natural large language models trained on public data accessible on the internet.
“Large Quantitative Models, such as those we use to causally filter through knowledge graphs, are proving impactful in many areas across the life sciences, from drug repurposing to reverse screening,” Harhen noted.
